Viewing data from:

IMIPRAMINE HYDROCHLORIDE

ANDA

IMIPRAMINE HYDROCHLORIDE | A040751 | OXFORD PHARMACEUTICALS LLC

3 strengths0 unique patents0 unique exclusivities

API Supply Chain2 active DMFs8 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

TAPI NL BVIMIPRAMINE HYDROCHLORIDE USP

DMF 19061972

LUPIN LTDIMIPRAMINE HYDROCHLORIDE USP

DMF 214382008

LUNDBECK PHARMACEUTICALS ITALY SPAInactiveIMIPRAMINE HYDROCHLORIDE

DMF 19131972

DELMAR CHEMICALS INCInactiveIMIPRAMINE HYDROCHLORIDE

DMF 21191973

IROPHARM LTDInactiveIMIPRAMINE HYDROCHLORIDE

DMF 65351986

ACF CHEMIEFARMA NVInactiveIMIPRAMINE HYDROCHLORIDE

DMF 67641987

SELOC AGInactiveIMIPRAMINE HYDROCHLORIDE

DMF 68061987

ARCHIMICA SPAInactiveIMIPRAMINE HYDROCHLORIDE

DMF 71901987

EGIS PHARMACEUTICALS PRIVATE LTDInactiveIMIPRAMINE HYDROCHLORIDE

DMF 79461989

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveIMIPRAMINE HYDROCHLORIDE USP

DMF 202982007

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 50MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Feb 28, 2008

No patent or exclusivity listings for this strength.

#002 — 25MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Feb 28, 2008

#003 — 10MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Feb 28, 2008